

Pneumocystis carinii (SPM365): sc-65527

BACKGROUND

Pneumocystis is a genus of fungi which can be pathogenic in mammals. *Pneumocystis carinii*, also referred to as *Pneumocystis jiroveci*, is a microscopic fungus that exists in the lungs of many humans. This fungus is normally benign, but it can cause *Pneumocystis carinii* pneumonia (PCP) in immunocompromised individuals. During PCP, *Pneumocystis carinii* deteriorates the basement membrane of the lung, causing a rise in LDH levels and compromising gas exchange. Oxygen is less able to diffuse into the blood, leading to hypoxia, which, along with high arterial CO₂ levels, stimulates ventilation, thereby causing dyspnea. The fungus can also invade other visceral organs, such as the liver, spleen and kidney. Symptoms of *Pneumocystis carinii* infection include shortness of breath, non-productive cough, low grade fever, weight loss and night sweats. This disease can be fatal if not treated aggressively.

REFERENCES

1. Pesanti, E.L. 1984. *Pneumocystis carinii*: oxygen uptake, antioxidant enzymes, and susceptibility to oxygen-mediated damage. *Infect. Immun.* 44: 7-11.
2. Feuerstein, I.M., Francis, P., Raffeld, M. and Pluda, J. 1990. Widespread visceral calcifications in disseminated *Pneumocystis carinii* infection: CT characteristics. *J. Comput. Assist. Tomogr.* 14: 149-151.
3. Oz, H.S., Hughes, W.T. and Vargas, S.L. 1996. Search for extrapulmonary *Pneumocystis carinii* in an animal model. *J. Parasitol.* 82: 357-359.
4. Späth, M. and Schollmeyer, P. 1997. *Pneumocystis carinii* and aspergillus pneumonia in immunosuppression in rapidly progressing glomerulonephritis of the anti-glomerular basement membrane type. *Medizinische Klinik* 91: 603-606.
5. Kroe, D.M., Kirsch, C.M. and Jensen, W.A. 1997. Diagnostic strategies for *Pneumocystis carinii* pneumonia. *Semin. Respir. Infect.* 12: 70-78.
6. Schwietert, M. 1999. Dyspnea, fever in immunodeficiency. *Pneumocystis carinii* pneumonia. *Schweiz. Rundsch. Med. Prax.* 88: 340-341.
7. Takahashi, T., Goto, M., Endo, T., Nakamura, T., Yusa, N., Sato, N. and Iwamoto, A. 2002. *Pneumocystis carinii* carriage in immunocompromised patients with and without human immunodeficiency virus infection. *J. Med. Microbiol.* 51: 611-614.
8. Stringer, J.R., Beard, C.B., Miller, R.F. and Wakefield, A.E. 2002. A new name (*Pneumocystis jiroveci*) for *Pneumocystis* from humans. *Emerging Infect. Dis.* 8: 891-896.
9. Roblot, F., Godet, C., Le Moal, G., Garo, B., Faouzi Souala, M., Dary, M., De Gentile, L., Gandji, J.A., Guimard, Y., Lacroix, C., Roblot, P. and Becq-Giraudon, B. 2002. Analysis of underlying diseases and prognosis factors associated with *Pneumocystis carinii* pneumonia in immunocompromised HIV-negative patients. *Eur. J. Clin. Microbiol. Infect. Dis.* 21: 523-531.

SOURCE

Pneumocystis carinii (SPM365) is a mouse monoclonal antibody raised against *Pneumocystis carinii* isolated from human lung.

PRODUCT

Each vial contains 200 µg IgM kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Pneumocystis carinii (SPM365) is recommended for detection of *Pneumocystis carinii* by immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500); non cross-reactive with *G. lamblia*, *T. gondii*, *T. cruzi*, *L. tropica*, *E. histolytica*, *C. albicans* and *P. falciparum*.

Molecular Weight of *Pneumocystis carinii*: 82 kDa.

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Immunofluorescence: use m-IgGκ BP-FITC: sc-516140 or m-IgGκ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz[®] Mounting Medium: sc-24941 or UltraCruz[®] Hard-set Mounting Medium: sc-359850. 2) Immunohistochemistry: use m-IgGκ BP-HRP: sc-516102 with DAB, 50X: sc-24982 and Immunohisto-mount: sc-45086, or Organo/Limonene Mount: sc-45087.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.